STOCK TITAN

[Form 4] Phathom Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Phathom Pharmaceuticals reported a Form 4 filing on June 28, 2025, disclosing stock option grants to Anne Marie Cook, the company's Chief Legal Officer & Corporate Secretary.

Key transaction details:

  • Granted 210,000 stock options to purchase common stock
  • Exercise price set at $9.47 per share
  • Grant date: June 23, 2025
  • Expiration date: June 22, 2035

The options follow a 4-year vesting schedule: 25% vests on June 23, 2026, with the remainder vesting in equal monthly installments over the following three years, contingent on continuous service. This grant appears to be part of the company's executive compensation program.

Phathom Pharmaceuticals ha comunicato una dichiarazione Form 4 il 28 giugno 2025, rivelando l'assegnazione di stock option a Anne Marie Cook, Chief Legal Officer e Segretario Aziendale della società.

Dettagli principali della transazione:

  • Assegnate 210.000 stock option per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 9,47 $ per azione
  • Data di assegnazione: 23 giugno 2025
  • Data di scadenza: 22 giugno 2035

Le opzioni seguono un piano di maturazione di 4 anni: il 25% matura il 23 giugno 2026, mentre il resto matura in rate mensili uguali nei successivi tre anni, subordinatamente alla continuità del servizio. Questa assegnazione sembra far parte del programma di compensazione esecutiva dell'azienda.

Phathom Pharmaceuticals presentó un Formulario 4 el 28 de junio de 2025, revelando la concesión de opciones sobre acciones a Anne Marie Cook, la Directora Legal y Secretaria Corporativa de la empresa.

Detalles clave de la transacción:

  • Concedidas 210,000 opciones sobre acciones para comprar acciones ordinarias
  • Precio de ejercicio establecido en $9.47 por acción
  • Fecha de concesión: 23 de junio de 2025
  • Fecha de vencimiento: 22 de junio de 2035

Las opciones siguen un programa de adquisición de derechos de 4 años: el 25 % se adquiere el 23 de junio de 2026, y el resto se adquiere en cuotas mensuales iguales durante los siguientes tres años, condicionado a la continuidad del servicio. Esta concesión parece formar parte del programa de compensación ejecutiva de la empresa.

Phathom Pharmaceuticals는 2025년 6월 28일 Form 4 신고를 통해 회사의 법무책임자 겸 기업 비서인 Anne Marie Cook에게 스톡 옵션 부여 사실을 공개했습니다.

주요 거래 내역:

  • 210,000주의 보통주 매수 권한 부여
  • 행사가격: 주당 $9.47
  • 부여일: 2025년 6월 23일
  • 만료일: 2035년 6월 22일

옵션은 4년 베스팅 일정에 따라 25%는 2026년 6월 23일에 베스팅되며, 나머지는 이후 3년 동안 매월 동일한 비율로 베스팅됩니다. 단, 지속 근무가 조건입니다. 이번 부여는 회사의 임원 보상 프로그램의 일환으로 보입니다.

Phathom Pharmaceuticals a déclaré un dépôt de formulaire 4 le 28 juin 2025, révélant l'octroi d'options d'achat d'actions à Anne Marie Cook, Directrice Juridique et Secrétaire Générale de l'entreprise.

Détails clés de la transaction :

  • Octroi de 210 000 options d'achat d'actions pour acquérir des actions ordinaires
  • Prix d'exercice fixé à 9,47 $ par action
  • Date d'octroi : 23 juin 2025
  • Date d'expiration : 22 juin 2035

Les options suivent un calendrier d'acquisition de droits de 4 ans : 25 % des options sont acquises le 23 juin 2026, le reste étant acquis par versements mensuels égaux sur les trois années suivantes, sous réserve d'une continuité de service. Cette attribution semble faire partie du programme de rémunération des cadres de l'entreprise.

Phathom Pharmaceuticals meldete am 28. Juni 2025 eine Form 4-Einreichung, in der Aktienoptionszuteilungen an Anne Marie Cook, die Chief Legal Officer und Unternehmenssekretärin des Unternehmens, offengelegt wurden.

Wesentliche Transaktionsdetails:

  • Gewährung von 210.000 Aktienoptionen zum Kauf von Stammaktien
  • Ausübungspreis festgelegt auf 9,47 $ pro Aktie
  • Gewährungsdatum: 23. Juni 2025
  • Ablaufdatum: 22. Juni 2035

Die Optionen folgen einem 4-jährigen Vesting-Zeitplan: 25 % werden am 23. Juni 2026 fällig, der Rest wird in gleichen monatlichen Raten über die folgenden drei Jahre erworben, vorausgesetzt die kontinuierliche Dienstzeit. Diese Zuteilung scheint Teil des Führungskräftevergütungsprogramms des Unternehmens zu sein.

Positive
  • None.
Negative
  • None.

Phathom Pharmaceuticals ha comunicato una dichiarazione Form 4 il 28 giugno 2025, rivelando l'assegnazione di stock option a Anne Marie Cook, Chief Legal Officer e Segretario Aziendale della società.

Dettagli principali della transazione:

  • Assegnate 210.000 stock option per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 9,47 $ per azione
  • Data di assegnazione: 23 giugno 2025
  • Data di scadenza: 22 giugno 2035

Le opzioni seguono un piano di maturazione di 4 anni: il 25% matura il 23 giugno 2026, mentre il resto matura in rate mensili uguali nei successivi tre anni, subordinatamente alla continuità del servizio. Questa assegnazione sembra far parte del programma di compensazione esecutiva dell'azienda.

Phathom Pharmaceuticals presentó un Formulario 4 el 28 de junio de 2025, revelando la concesión de opciones sobre acciones a Anne Marie Cook, la Directora Legal y Secretaria Corporativa de la empresa.

Detalles clave de la transacción:

  • Concedidas 210,000 opciones sobre acciones para comprar acciones ordinarias
  • Precio de ejercicio establecido en $9.47 por acción
  • Fecha de concesión: 23 de junio de 2025
  • Fecha de vencimiento: 22 de junio de 2035

Las opciones siguen un programa de adquisición de derechos de 4 años: el 25 % se adquiere el 23 de junio de 2026, y el resto se adquiere en cuotas mensuales iguales durante los siguientes tres años, condicionado a la continuidad del servicio. Esta concesión parece formar parte del programa de compensación ejecutiva de la empresa.

Phathom Pharmaceuticals는 2025년 6월 28일 Form 4 신고를 통해 회사의 법무책임자 겸 기업 비서인 Anne Marie Cook에게 스톡 옵션 부여 사실을 공개했습니다.

주요 거래 내역:

  • 210,000주의 보통주 매수 권한 부여
  • 행사가격: 주당 $9.47
  • 부여일: 2025년 6월 23일
  • 만료일: 2035년 6월 22일

옵션은 4년 베스팅 일정에 따라 25%는 2026년 6월 23일에 베스팅되며, 나머지는 이후 3년 동안 매월 동일한 비율로 베스팅됩니다. 단, 지속 근무가 조건입니다. 이번 부여는 회사의 임원 보상 프로그램의 일환으로 보입니다.

Phathom Pharmaceuticals a déclaré un dépôt de formulaire 4 le 28 juin 2025, révélant l'octroi d'options d'achat d'actions à Anne Marie Cook, Directrice Juridique et Secrétaire Générale de l'entreprise.

Détails clés de la transaction :

  • Octroi de 210 000 options d'achat d'actions pour acquérir des actions ordinaires
  • Prix d'exercice fixé à 9,47 $ par action
  • Date d'octroi : 23 juin 2025
  • Date d'expiration : 22 juin 2035

Les options suivent un calendrier d'acquisition de droits de 4 ans : 25 % des options sont acquises le 23 juin 2026, le reste étant acquis par versements mensuels égaux sur les trois années suivantes, sous réserve d'une continuité de service. Cette attribution semble faire partie du programme de rémunération des cadres de l'entreprise.

Phathom Pharmaceuticals meldete am 28. Juni 2025 eine Form 4-Einreichung, in der Aktienoptionszuteilungen an Anne Marie Cook, die Chief Legal Officer und Unternehmenssekretärin des Unternehmens, offengelegt wurden.

Wesentliche Transaktionsdetails:

  • Gewährung von 210.000 Aktienoptionen zum Kauf von Stammaktien
  • Ausübungspreis festgelegt auf 9,47 $ pro Aktie
  • Gewährungsdatum: 23. Juni 2025
  • Ablaufdatum: 22. Juni 2035

Die Optionen folgen einem 4-jährigen Vesting-Zeitplan: 25 % werden am 23. Juni 2026 fällig, der Rest wird in gleichen monatlichen Raten über die folgenden drei Jahre erworben, vorausgesetzt die kontinuierliche Dienstzeit. Diese Zuteilung scheint Teil des Führungskräftevergütungsprogramms des Unternehmens zu sein.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cook Anne Marie

(Last) (First) (Middle)
C/O PHATHOM PHARMACEUTICALS, INC.
100 CAMPUS DRIVE, SUITE 102

(Street)
FLORHAM PARK NJ 07932

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Off. & Corp. Sec.
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $9.47 06/23/2025 A 210,000 (1) 06/22/2035 Common Stock 210,000 $0 210,000 D
Explanation of Responses:
1. The stock option will vest with respect to 25% of the shares of common stock on June 23, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.
/s/ Anne Marie Cook 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did PHAT's Chief Legal Officer receive on June 23, 2025?

PHAT's Chief Legal Officer Anne Marie Cook received 210,000 stock options (right to buy) on June 23, 2025, with an exercise price of $9.47 per share.

What is the vesting schedule for PHAT CLO's June 2025 stock options?

The stock options vest 25% on June 23, 2026 (first anniversary), with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service with PHAT.

When do PHAT's stock options granted to Anne Marie Cook expire?

The stock options granted to Anne Marie Cook expire on June 22, 2035, ten years from the grant date.

What is the exercise price of PHAT's stock options granted to their Chief Legal Officer in June 2025?

The exercise price of the stock options granted to PHAT's Chief Legal Officer is $9.47 per share.
Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

PHAT Rankings

PHAT Latest News

PHAT Latest SEC Filings

PHAT Stock Data

727.46M
54.40M
3.77%
97.01%
20.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
FLORHAM PARK